BIOMARIN PHARMACEUTICAL INC Finance Lease, Right-of-Use Asset, after Accumulated Amortization
BIOMARIN PHARMACEUTICAL INC (BMRN) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $4.05 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2026-02-26
- 2025-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $4.05M.
- 2024-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $5.07M.
- 2023-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $3.34M.
- 2022-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $6.02M.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2025-12-31 | $4.05M 10-K · filed 2026-02-26 |
| 2024-12-31 | $5.07M 10-K · filed 2026-02-26 |
| 2023-12-31 | $3.34M 10-K · filed 2025-02-24 |
| 2022-12-31 | $6.02M 10-K · filed 2024-02-26 |
| 2021-12-31 | $8.22M 10-K · filed 2023-02-27 |
| 2020-12-31 | $11.10M 10-K · filed 2022-02-25 |
| 2020-09-30 | $12.02M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $9.38M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $9.70M 10-Q · filed 2020-05-01 |
| 2019-12-31 | $10.39M 10-K · filed 2021-02-26 |
| 2019-09-30 | $10.35M 10-Q/A · filed 2019-11-04 |
| 2019-06-30 | $8.60M 10-Q · filed 2019-08-02 |
| 2019-03-31 | $9.20M 10-Q · filed 2019-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |